CER-001 infusion ameliorated systemic endothelial dysfunction by reducing VCAM-1 (Fig. 1H) and ICAM-1 (Fig. 1I) serum levels in both treated groups, with an increased effect of the two doses of ApoA-I complexes as emphasized at T6 time points. The gene discussed is ICAM1; the disease is endothelial dysfunction.